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Summary The management of patients presenting with metastatic malignant melanoma (MM) is hampered
by the substantial variability in survival of these patients and the lack of prognostic markers. In the search for
a reliable predictive parameter, we have investigated the expression of the nm23 gene, considered to be a major
regulator of the metastatic process. We have analysed by Northern blot the nm23 mRNA level in tumour
tissue obtained from metastases of 20 stage II and ten stage III patients with MM. Normal human tissues and
benign naevi were simultaneously examined. The level of nm23 expression was highly heterogeneous in MM
metastases, with a mean value which was higher than the mean level in normal tissues and naevi. Correlative
study was focused on the overall survival following resection of the metastasis in which nm23 Northern blot
analysis was performed. Patients displaying higher nm23 expression in metastatic tissue (above the mean level)
tended to have a longer survival than others (P = 0.08), and this difference was significant for patients
presenting with isolated regional lymph node involvement (P = 0.035). The time from biopsy of the primary
MM to the appearance of the first lymph node metastasis also showed a positive correlation with the nm23
mRNA level in this metastasis. The present study is not only in accordance with previous reports showing that
the nm23 gene may be implicated in MM progression, but also suggests the reliable value of nm23 expression
as a prognostic marker for patients presenting with metastatic MM.
Current methods to identify the aggressive potential ofmalig-
nant melanoma (MM) are limited. Even after occurrence of
regional lymph node metastasis, patients may either pursue
an indolent clinical course or rapidly die. The search for
reliable prognostic parameters therefore appears vitally
important in order to ensure adequate therapy, especially for
advanced MM stages which are candidates for non-surgical
treatment.
The production of clinically relevant metastasis is triggered
by a complex series of linked sequential steps, some being
genetically regulated by transient or permanent alterations at
the DNA or mRNA level. The nm23 gene is thought to play
a major role in this network of triggering signals (Rosengard
et al., 1989; Leone et al., 1991). This gene was identified by
differential colony hybridisation between related low- and
high-metastatic murine k-1735 melanoma cell lines, a tumour
system which contains clonal populations with qualitative
differences in metastatic capacity in syngenic mice (Steeg et
al., 1988). mRNA levels of the nm23-1 gene were found to be
approximately 10-fold higher in low-metastatic potential
clones than in highly metastatic clones (Steeg et al.,
1988).
In human tumours, contradictory results were reported on
nm23 gene expression. Reduced expression was found in
primary, infiltrating ductal breast carcinomas with metastases
in regional lymph nodes present at diagnosis (Bevilacqua et
al., 1989; Hennessy et al., 1991). Low nm23 expression in
breast tumours also correlated with decreased survival
(Barnes et al., 1991). These findings, however, cannot be
generalised since low nm23 expression does not clearly imply
poor prognosis in other types of human tumours such as
colorectal carcinoma or neuroblastoma (Cohn et al., 1991;
Hailat et al., 1991; Haut et al., 1991). The prognostic value
of the nm23 gene transcriptional activity in MM is suggested
by the fact that this gene was originally cloned from murine
melanoma cells, and also by some preliminary observations
in human MM (Florenes et al., 1992). In this report, we have
tried to investigate the significance of nm23 expression as a




Tumoral tissue samples from 30 patients with MM were
obtained through surgery. These patients were classified as
stage II (regional lymph node involvement, n = 20) or stage
III (distant lymph node involvement or visceral metastasis,
n = 10). The histopathological characteristics of the primary
cutaneous MM are detailed in Table I.
Each biopsy specimen was histologically identified as
metastasis of MM involving lymph node in 25 cases, skin in
four cases and liver on one case. A part of each fresh sample
was stored in liquid nitorgen.
In addition, eight samples of human normal tissues (liver,
breast, prostate, lymph node, spleen and ovary) as well as
three benign naevi were analysed.
Northern blot analysis
Total RNA was isolated from frozen tissues by the
guanidinium thiocyanate-caesium chloride method as previ-
ously described (Maniatis et al., 1982).
Integrity of each RNA sample was ensured by (i) electro-
phoresis of a 2 ,sg aliquot on denaturing agarose-formal-
dehyde gel; and (ii) reverse transcription and polymerase
chain reaction (PCR) amplification of the human GAPDH
gene, which is expressed in almost all types of tissues. North-
ern blots were performed by running 10 gsg of RNA on
denaturing gels and transferring onto Hybond nylon mem-
branes as indicated by the manufacturer (Amersham,
UK).
The filters were UV cross-linked and hybridised to the
nm23-H1 cDNA probe (a 900 bp BamHI fragment from
pNM23-Hl plasmid, kindly provided by Dr P.-S. Steeg, NCI,
Bethesda, MD, USA). Filters were then stripped and rehy-
bridised to a cDNA probe specific for human GAPDH to
correct for the unequal amount of RNA loaded in each lane.
The level of nm23 mRNA was adjusted relative to the
amount of GAPDH RNA after densitometric scanning of the
autoradiograms. GAPDH was chosen as an internal standard
because this gene is refractory to transcriptional induction by
various agents and is known to show a relatively constant
expression among most tissues (Bosma & Kooistra, 1991;
Zentella et al., 1991).
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Statistical analysis
Clinical and follow-up data were available in all patients and
attempts were made to correlate nm23 expression with prog-
nosis.
Statistical evaluation was performed by BMDP package
program. The proportion surviving was estimated by Kap-
lan-Meier method and compared by Mantel-Cox test.
Results
nm23 expression
The level of nm23 expression was expressed as a percentage
of the GAPDH mRNA level.
The mean level of nm23 expression in eight normal tissues
samples, i.e. liver, breast, prostate, lymph node, spleen and
ovary (65%) was approximately similar to the mean nm23
level in three benign naevi.
In the group with MM, expression was highly
heterogeneous, ranging from 7% to 240% (Figure 1; Tables I
and II).
Clinical correlations
A summary of statistical data is given in Table III.
Mean overall survival following metastasis resection was
21.6 months among the whole population of 30 patients.
Within this population, patients with nm23 RNA content
above the mean level of nm expression (46.9%) tended to do
better than others: P = 0.08 (Figure 2 and Table II). Further-
more, among the 20 patients presenting with only regional
lymph nodes (stage II) at the time of Northern blot analysis,
there was a significant correlation between nm23 RNA level
in the metastatic lymph node and the overall survival taking
the node resection as a starting point. Indeed, stage II
patients displaying nm23 expression above the mean level had
a longer survival than others: P = 0.035 (Figure 3 and Table
II).
Unlike the overall survival, the disease-free interval (from
resection of the analysed metastasis to the occurrence of
relapse) was not significantly different among stage II
patients with nm23 expression above or below the mean level:
P = 0.48 (Figure 4).
When the time of primary tumour resection was chosen as
a starting point, a significant positive relation was observed
between the time interval until the occurrence of the first
metastasis and the nm23 level in this metastasis. Indeed,
among the subgroup of patients who had presented initially
as stage I (isolated cutaneous tumour) and evaluated for
nm23 level in the first known metastasis (n = 15), the disease
progression was slower in patients with nm23 above the
median level (28%): P = 0.04 (Figure 5 and Table II). The
median nm23 level was chosen as reference in this subgroup
because almost all patients were above the mean level.
In addition, it must be noted that, at the time of lymph
node metastasis resection, patients presenting with more
disseminated disease (lymph node metastasis associated with
involvement of other organs including skin) expressed lower
nm23 levels (mean 31%) than patients harbouring a single
lymph node metastasis (mean 51%), but the difference was
not significant.
There was no significant correlation between nm23 expres-
sion and histological typing of primary cutaneous MM
(Table I).
Table I Correlations between nm23 expression in metastasis and
histopathological characteristics of primary melanoma
nm23 Histological Breslow
Cases expressiona type Clark (MM)
1 7 NM IV 4
2 10 NM IV 1.5
3 11 SSM IV 2
4 14 ALM III 1.5
5 14 ALM III 1.4
6 16 SSM IV 2.7
7 17 ALM V 5
8 20 SSM II 0.6
9 22 SSM II 0.8
10 22 SSM III 1.4
11 22 SSM IV 2.5
12 25 SSM III 1.95
13 25 NM IV 2.0
14 26 NM II 0.9
15 28 ALM IV 3.3
16 28 NM III 2.4
17 29 ALM IV 3.6
18 31 SSM III 1.4
19 35 SSM IV 1
20 41 SSM III 1.4
21 46 SSM IV 1.6
22 47 ALM III 1.5
23 49 SSM III 1.1
24 52 SSM IV 2.5
25 63 NM III 1.4
26 78 NM IV 6
27 81 SSM IV 5.8
28 88 Unclassified V 14
29 218 Primary tumour unknown
30 240 NM III 1.4
aAnalysed on early or late metastasis.
nm23
GAPDH
Figure 1 Northern blot analysis showing the nm23 mRNA level in normal tissues, benign naevi and metastases of melanoma.
Total RNA was hybridised to the 900bp BamHI fragment of nm23-Hl cDNA (top) and as a control to a GAPDH probe
(bottom). Lanes A-C, normal tissues from liver, breast and prostate; lanes D-F, benign naevi; lanes G-X, metastases of
melanoma.1226 L. XERRI et al.
Table II Correlations between nm23 expression, overall survival
from the time of nm23 analysis, disease-free interval from the time of
primary tumour resection and clinical staging
Interval
Overall from
nm23 survival primary Clinical
Cases expressiona (months)' tumourc stagingd
1 7 (<m) 16 II
2 10(<m) 7 II
3 11 (<im) 7 II
4 14 (<im) 4 16 III
5 14(<m) 8 II
6 16 (<im) 6 III
7 17(<m) 2 11
8 20 (<im) 9 III
9 22 (<im) 11 46 II
10 22 (<im) 29 III
11 22 (<im) 17 11 II
12 25 (<im) 11 20 II
13 25 (<im) 9 III
14 26 (<im) 3 21 III
15 28 (<im) 2 II
16 28 (<im) 20 III
17 29 (<im) 20 29 II
18 31 (<im) 4 35 II
19 35 (<im) 4 26 II
20 41 (<m) 10 34 II
21 46 (<im) 5 60 II
22 47 (>m) 15 32 II
23 49 (>m) 9 54 III
24 52 (>m) 5 III
25 63 (>m) 12 1 II
26 78 (>m) 14 III
27 81 (>m) 8 II
28 88 (>m) 33 II
29 218 (>m) 10 II
30 240 (>m) 22 11 II
aAnalysed on early or late metastasis. (<m) and (>m) refer to
the mean level of nm23 expression (46.9%), calculated in the whole
population of 30 samples. bFrom the time of metastasis resection, i.e.
from nm23 Northern blot anaysis. cDisease-free interval from
resection of the primary cutaneous MM until occurrence of the first
metastasis (restricted to 15 patients who had presented initially
without metastasis and for whom nm23 analysis could be performed
on the first metastasis). dStage II, regional lymph node metastasis;
stage III; visceral or disseminated metastases.
Table III Summary of statistical correlations between nm23
expression and patients' outcome
P-value
Correlation betwveen NM23expression and (Mantel-Cox)
Overall survival from metastasis resection amongall 0.08
patients
Overall survival frommetastasis resection among 0.035
stage IIpatients
Disease-free survival frommetastasis resection 0.48
among stage IIpatients
Timeinterval from primary MM resection to first 0.04
metastasisamongstage Ipatients
Discussion
Recent evidence indicates that the human nm23-H gene is
located in 17q21.3, a chromosomal region known to contain
the locus for early-onset familial breast-ovarian cancer and
other genes involved in tumorigenesis (Steeg et al., 1988;
Leone et al., 1991). This gene encodes one subunit of the
enzyme NDP kinase (Gilles et al., 1991) and is structurally
related to the human nm23-H2 gene encoding a second sub-
unit of NDP kinase and co-localising with nm23-H1 in this
region (Stahl et al., 1991). nm23 genes have also substantial
homology with the predicted product of the Drosophila
melanogaster developmental gene for abnormal wing discs
(awd), which shows NDP kinase activity (Biggs et al., 1990).
.5
en












i I i I
0 4 8 12 16 20 24 28 32
Months
36
Figure 2 Kaplan-Meier graph showing the relationship between
nm23 level in metastasis and overall survival following metastasis
resection among the whole patient population, regardless of stag-
ing. The 30 cases were divided into two groups according to
respective nm23 level compared with the mean nm23 expression
(46.9%). Patients with nm23 expression above the mean level
tended to do better (A) than others (U), but the difference was




Figure 3 Kaplan-Meier graph showing the relationship between
nm23 level in lymph node metastasis and overall survival follow-
ing metastasis resection in stage II patients. The 20 cases were
divided into two groups according to nm23 expression compared
with the mean nm23 level (46.9%). Significantly longer survival
was observed among patients with nm23 expression above the
mean level (A), when compared with others (U) (P = 0.035).
It has been postulated that NDP kinase may participate in
signal transduction through G-proteins (Stryer, 1986).
Although demonstration has been provided that the nm23
gene may act as a metastasis-suppressor gene in at least some
experimental models (Henderson, 1993), the role of nm23 is
still unclear in human cancer. Attempts to use tumour levels
of nm23 expression as a predictive marker have given rise to
contradictory findings.
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Figure 4 Kaplan-Meier graph showing the relationship between
nm23 level in lymph node metastasis and disease-free survival
following metastasis resection in stage II patients. Correlations
were analysed in a way similar to Figure 3. There was no
significant difference in survival (P = 0.48).
In some breast tumours, evidence suggesting that low nm23
mRNA levels may indicate a poor prognosis could be
demonstrated, based on the fact that patients whose tumours
showed reduced nm23-Hl expression had a higher rate of
lymph node metastasis and reduced survival (Bevilacqua et
al., 1989; Hennessy et al., 1991; Barnes et al., 1991). In
colorectal carcinoma however, nm23 expression correlated
only with the occurrence of liver metastasis but not with
lymph node involvement (Haut et al., 1991; Yamagushi et al.,
1993). In addition, human colon carcinomas were found to
exhibit enhanced nm23 mRNA expression compared with
normal mucosa (Yamagushi et al., 1993). Moreover, in-
creased nm23 protein levels were observed, surprisingly, in
advanced-stage neuroblastoma (Hailat et al., 1991).
,A recent report has suggested that expression of the nm23
gene may be related to rapid progression in patients with
MM. Florenes et al. (1992) observed that the nm23 mRNA
level tended to be higher in secondary tumours occurring
after prolonged relapse-free interval from primary diagnosis.
Nonetheless, this study was only retrospective and did not
attempt to show the usefulness of nm23 expression as a
predictive parameter of prognosis.
The prognosis of patients with advanced MM actually
remains poorly defined, since substantial variability in sur-
vival can be observed. In patients with regional nodal disease
(stage II), the likelihood of systemic recurrence has been only
correlated with the size and number of involved nodes, cap-
sular effraction and more recently with some biological
parameters (Sirott et al., 1993).
In the present report, we have tried to investigate the
significance of nm23 expression as a prognostic marker for
MM patients who have developed metastasis (stage II or III).
We have therefore focused our study on the link between this
expression and the time from biopsy of metastasis to the
death of the patient (overall survival).
Our results proved to be of particular interest with regard
to patients presenting with regional node invasion (stage II)
at the time of Northern blot analysis. Among this subgroup,
overall survival following metastasis resection was indeed
significantly longer for patients with nm23 expression in
metastasis above the mean level. These data are not only in
accordance with a putative relationship between nm23 trans-
criptional level and progression of the disease, as suggested
by Florenes et al. (1992), but they also provide the additional




Figure 5 Relationship between nm23 levels in the first metastasis
and the disease-free interval from resection of the primary
cutaneous MM to the occurrence of metastasis. This graph is
restricted to 15 patients who had presented initially without
metastasis and for whom nm23 analysis could be performed on
the first metastasis. Patients were divided into two groups accord-
ing to nm23 expression compared with the median nm23 level
(28%). Longer intervals were observed among patients with nm23
expression above the median level (A), when compared with
others (A): P= 0.04.
From a theoretical standpoint, some of our findings also
seem noteworthy, although devoid of practical value. The
fact that nm23 levels in the first known metastasis were
related to the interval of time from primary MM diagnosis
further supports the hypothesis that the nm23 gene may
regulate at least some steps of the metastatic process in
human MM.
Nonetheless, the mechanism by which the nm23 gene may
be implicated in tumour progression still remains far from
clear since, in contrast to what should have been expected,
some of our MM metastasis samples exhibited higher level of
nm23 expression than benign naevi and normal tissues.
Similar findings were reported by Florenes et al. (1992). In
this context, it must also be pointed out that nm23 expression
in colon cancer can be higher than in normal surrounding
mucosa (Yamagushi et al., 1993). An explanation for the low
amounts of nm23 product which can be observed in normal
or benign neoplastic tissue may be that the nm23 gene may
play different roles in differentiated the malignant cells. With
regard to the unexpectedly high nm23 RNA level in some
aggressive tumours, it may also be suggested that nm23
molecular alterations, other than reduced expression, may
result in aggressive tumoral behaviour. This hypothesis
appears relevant in at least some cases of aggressive neuro-
blastoma harbouring nm23 genomic amplification and muta-
tion (Hailat et al., 1991).
In conclusion, the present study suggests the prognostic
value of nm23 expression in the practical management and
therapeutic strategy of MM patients and should now be
confirmed by larger series and clinical trials.
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